Lazcluze (lazertinib tablets) — Medica
Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations
Initial criteria
- age ≥ 18 years
- patient has locally advanced or metastatic disease
- patient has EGFR exon 19 deletion or exon 21 L858R substitution mutation detected by an approved test
- medication is used in combination with Rybrevant (amivantamab-vmjw intravenous infusion)
Approval duration
1 year